The New Kid on the Block: Implementation of the Newly FDA-Cleared Scopio Labs™ X100 with Full Field Peripheral Blood Smear Application for Research and Training During the COVID-19 Pandemic

Christian Salib, M.D.
Assistant Professor, Hematopathology
Icahn School of Medicine at Mount Sinai, New York, NY
DISCLOSURE

The authors of this abstract have indicated that they have no conflicts of interest that relate to the content of the material being presented.
BACKGROUND

• Digital pathology and artificial intelligence (AI) is a rapidly growing field of Pathology.

• A growing number of institutes have integrated digital imaging into routine workflow, relying on AI algorithms for the detection of prostate cancer, mitotic figure enumeration and evaluating degree of glomerular disease.

• Despite advances of Whole Slide Imaging (WSI) for tissue evaluation, the field of Hematopathology and Cytology has lagged behind other subspecialties.
BACKGROUND

• The new Scopio Labs X100 digital imaging instrument was implemented, which provides high resolution oil-immersion level images, allowing for clear and accurate detection of single cells in body fluid smears with high fidelity.

To the best of our knowledge, we are first among a handful of institutions to implement the Scopio Labs X100 digital slide imaging for bone marrow aspirates (BMA), cytology and peripheral blood smears (PBS) for research and training purposes.
**Data obtained was covered under an IRB waiver, HS#:12-00133 GCO#1:12-036(0001-08)**
CONCLUSION

• The Scopio Labs X100 digital system is an accurate and efficient web-based digital tool and image bank to accommodate the social distancing challenges during the COVID-19 pandemic for Hematologists, Hematopathologists, Cytopathologists and trainees alike.

• With its recent FDA-clearance, we aim to fully integrate Scopio Labs into our LIS and assess the full field PBS application to streamline our workflow.